Hims vs Medvi: How the Two GLP-1 Programs Are Built

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

This comparison is independent editorial content. PlexusDx has no commercial relationship with Hims or Medvi, and it contains no affiliate links or paid endorsements.

Searchers comparing Hims and Medvi are typically choosing between a large consumer telehealth brand and a compounding-focused program. The two are built on different commercial logic, yet they meet at the same set of GLP-1 molecules. This piece maps where each sits, how prescribing works, and the one input that decides context rather than convenience. Both are among many programs live in April 2026.

Where Hims sits in the telehealth landscape

Hims (part of Hims & Hers Health) operates as subscription telehealth, offering a virtual clinical evaluation, provider-issued prescriptions, and dispensing of either brand-name FDA-approved GLP-1 therapy or compounded semaglutide and tirzepatide via licensed compounding pathways. Its weight-loss program is described at Hims's official website. The draw is scale and a familiar, streamlined consumer interface.

Where Medvi sits in the telehealth landscape

Medvi (Medvi Wellness) is organized around a telehealth-plus-compounded-pharmacy pipeline. Its medication options and pricing move over time, so Medvi's official website holds the terms in force when you read this. Across the category, monthly totals commonly fall in the $200—$700+ band once evaluation fees, medication, and dispensing are combined.

Prescribing pathway: brand-name versus compounded

The decision that actually shapes a program is dispensing pathway. A branded FDA-approved product and a compounded preparation of the same molecule differ in sourcing and labeling, but not in mechanism. Whether you enroll with a large consumer brand or a compounding-first service, what you receive is defined by molecule and preparation — the interface, the marketing, and the size of the company around it are secondary to what the pharmacy actually dispenses and how a clinician oversees it.

The molecule does the work, not the platform

The compound class carries the evidence. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide modulate appetite, satiety, and gastric emptying, documented across STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). A recognizable brand name does not add to that record; the molecule does the work, and the trial results follow the compound and dose regardless of which platform hands it to you.

Reading your metabolic baseline

No checkout flow reads the genetics beneath your metabolism. Variants in FTO, GLP1R (the biological target of every GLP-1 compound), MC4R, and TCF7L2 describe the appetite and glucose-handling terrain any protocol enters. They are pathway-level, not response predictors, but they matter to the decision. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across those genes.

Adding genetic context with PlexusDx

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with the genetic read attached. That upstream step is what separates it from a brand-first sign-up.

Not affiliated: PlexusDx has no commercial ties to Hims or Medvi and was not compensated for this review.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hims or Medvi and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

What kind of program is Hims?

Hims operates as subscription telehealth under Hims & Hers Health, combining virtual evaluation with provider-issued prescriptions and dispensing. Its appeal is scale and a streamlined consumer experience. Medvi, by contrast, is organized around a compounding pharmacy pipeline. Current terms for each are posted on their own sites.

Is a big brand like Hims safer than Medvi?

Brand size does not by itself determine safety; dispensing pathway, provider oversight, and pharmacy licensing do. Both operate in regulated telehealth. What matters is the specific medication, its preparation, and the clinical review behind it — details you should confirm directly with each program.

Can the genetic test predict how I will respond to a GLP-1?

No. The Precision Peptide Genetic Test does not predict response to any compound or program. It maps pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline biology, offering context to review with a provider rather than a prediction.

How is PlexusDx different from Hims?

PlexusDx offers semaglutide and tirzepatide with an upstream genetic read that a brand-first checkout does not include. The pathway-level insight on FTO, MC4R lets you enter the medication decision informed instead of enrolling by default, adding biological context that a streamlined consumer sign-up simply is not designed to surface.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education